Saturday 17 October 2026
Export ACET’s income statement to Excel — free account
Adicet Bio, Inc.
ACET Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.4% and free cash flow grew 24.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.57
0.57
−11.09%
Follow ACET
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
6.57 | 7.52 | 7.36 | 5.44 | |
Current Ratio |
6.71 | 7.66 | 7.47 | 5.62 | |
Net Debt/EBITDA |
5.41 | 6.51 | 5.00 | 3.78 | |
Debt/Assets |
0.42% | 0.51% | 0.33% | 0.45% | |
Debt/Equity |
0.01 | 0.01 | 0.00 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 1.06 | 0.69 | 0.83 | |
Capex/Depreciation |
(0.36) | (0.07) | 0.03 | (0.24) | |
Interest Coverage |
(1,013.68) | (937.83) | (1,328.54) | (2,329.33) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.84) | (2.00) | (3.03) | (3.92) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | (0.04) | |
Free Cash Flow per Share |
(1.86) | (2.00) | (3.03) | (3.96) | |
Cash per Share |
11.00 | 12.81 | 23.00 | 18.11 | |
Shareholders Equity per Share |
11.18 | 13.04 | 23.10 | 19.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.18 | 13.04 | 23.10 | 19.17 | |
Free Cash Flow |
(20.02) | (21.53) | (20.90) | (22.52) | |
Working Capital |
102.76 | 121.77 | 139.40 | 87.55 | |
Capital Expenditures |
(0.20) | (0.04) | 0.01 | (0.21) | |
Net Current Asset Value |
92.74 | 110.75 | 127.78 | 75.16 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.44 | 3.67 | 4.78 | 3.39 | |
Average Assets |
155.57 | 180.33 | 206.29 | 193.22 | |
Average Common Equity |
126.76 | 150.76 | 172.91 | 160.34 |
Columns are period end dates